Generic Name:
lutetium vipivotide tetraxetan
Project Status:
Active
Therapeutic Area:
Metastatic castration-resistant prostate cancer
Manufacturer:
Advanced Accelerator Applications USA, Inc.
Call for patient/clinician input open:
Brand Name:
Pluvicto
Project Line:
Reimbursement Review
Project Number:
PC0297-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule E
Tumour Type:
Genitourinary
Indications:
The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.